Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APREGet Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 117,100 shares, an increase of 66.8% from the February 29th total of 70,200 shares. Based on an average trading volume of 35,700 shares, the short-interest ratio is presently 3.3 days. Approximately 3.8% of the shares of the company are short sold.

Analysts Set New Price Targets

Several brokerages have recently issued reports on APRE. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday. Wedbush boosted their price target on Aprea Therapeutics from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday.

Check Out Our Latest Report on Aprea Therapeutics

Insider Buying and Selling

In other news, Director Bernd R. Seizinger acquired 6,860 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The shares were purchased at an average cost of $7.29 per share, for a total transaction of $50,009.40. Following the transaction, the director now directly owns 33,685 shares in the company, valued at approximately $245,563.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 9,870 shares of company stock valued at $71,952 in the last quarter. Company insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Aprea Therapeutics by 26.9% in the fourth quarter. Vanguard Group Inc. now owns 34,688 shares of the company’s stock valued at $163,000 after purchasing an additional 7,347 shares in the last quarter. Royal Bank of Canada boosted its position in Aprea Therapeutics by 13,788.0% during the 4th quarter. Royal Bank of Canada now owns 44,025 shares of the company’s stock worth $207,000 after acquiring an additional 43,708 shares during the period. Geode Capital Management LLC acquired a new position in shares of Aprea Therapeutics in the 2nd quarter valued at about $74,000. Millennium Management LLC lifted its position in shares of Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after purchasing an additional 43,293 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC acquired a new stake in shares of Aprea Therapeutics during the third quarter worth approximately $40,000. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Stock Up 10.2 %

Shares of APRE opened at $6.69 on Friday. Aprea Therapeutics has a 52-week low of $2.78 and a 52-week high of $8.85. The firm has a market capitalization of $25.02 million, a PE ratio of -1.68 and a beta of 1.05. The firm has a 50-day moving average price of $6.39 and a 200 day moving average price of $5.01.

Aprea Therapeutics Company Profile

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.

Read More

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.